Study Reveals Importance Of Timing For Cellular Signals, Suggests Possible Tactic For Cancer Therapeutics
Magic tricks work because they take advantage of the brain’s sensory assumptions, tricking audiences into seeing phantoms or overlooking sleights of hand. Now a team of UC San Francisco researchers has discovered that even brainless single-celled yeast have sensory biases that can be hacked by a carefully engineered illusion, a finding that could be used to develop new approaches to fighting diseases such as cancer.
“The ability to perceive and respond to the environment is a basic attribute of all living organisms, from the greatest to the smallest,” said Wendell Lim, PhD, the study’s senior author. “And so is the susceptibility to misperception. It doesn’t matter if the illusion is based on molecular sensors within a single cell or neurons in the brain.”
In the new study, published online Nov. 19, 2015 in Science Express, Lim and his team discovered that yeast cells falsely perceive a specifically timed pattern of stress – caused by alternating between low and mildly increased sodium levels – as a massive, continuously increasing ramp of stress. In response, the microbes end up over-responding and killing themselves. The results, Lim says, suggest a whole new way of looking at the perceptual abilities of simple cells and could even be used to develop new approaches to fighting diseases using the power of illusion.
Timing of stress response is yeast cells’ ‘Achilles heel’
“This discovery was a bit of an accident actually,” said Lim, chair of the Department of Cellular and Molecular Pharmacology at UCSF, director of the UCSF Center for Systems and Synthetic Biology, and a Howard Hughes Medical Institute (HHMI) investigator. “We were interested in the general issue of how cells interpret information over time. Frequency is a key aspect of all our communications, whether it’s hearing language or transmitting radio signals, but do cells themselves use this kind of information? It’s something we don’t know much about.”
To explore this question, two postdoctoral fellows in Lim’s lab, Ping Wei, PhD, now at Peking University School of Life Sciences, and Amir Mitchell, PhD, set up a system that allowed them to expose yeast to a mild stressor – a small increase in salt in the yeast’s environment – and to oscillate between the increased salt level and the baseline level at different frequencies.
Normally, sensor molecules in a yeast cell detect changes in salt concentration and instruct the cell to respond by producing a protective chemical. After this transient response, the cell can resume growing happily as if conditions had not changed. The researchers found that the cells were perfectly capable of adapting when they flipped the salt stress on and off every minute or every 32 minutes. But to their surprise, when they tried an eight-minute oscillation of precisely the same salt level the cells quickly stopped growing and began to die off.
“That was just a jaw-dropping moment,” said Mitchell. “These cells should be able to handle this level of osmotic stress, but at one particular frequency they just go haywire. We’d never seen anything like this before.”
Could sensory illusions be used to fight cancer?
Mitchell, who was first author on the new study, went on to inspect the cellular mechanism underlying this unexpected, frequency-dependent toxicity. Using mathematical modeling and experiments in which he tweaked the molecular wiring of the mitogen activated protein kinase (MAPK) pathway that mediates the cells’ salt-sensing system, he revealed a sensory misperception: Because of the way the MAPK pathway is set up, the cells interpret an eight-minute oscillation as an ever-increasing staircase of salt concentration. This leads to excessive activation of the cells’ protective response, and ultimately to their death (see Movie).
The Latest on: Cancer Therapeutics
via Google News
The Latest on: Cancer Therapeutics
- Amgen To Acquire Five Prime Therapeutics - Quick Factson March 5, 2021 at 1:19 am
Amgen (AMGN) has agreed to acquire Five Prime Therapeutics (FPRX) for $38.00 per share in cash, representing an equity value of ...
- ONA Therapeutics appoints Mark Throsby to its Board of Directorson March 5, 2021 at 12:00 am
Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic ...
- Peptide Based Cancer Therapeutics Market Analysis with Key Players, Applications, Trends and Forecasts to 2027on March 4, 2021 at 11:31 pm
Selbyville, Delaware According to a recent study titled 'Peptide Based Cancer Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Type; By Mode of Mechanism, By Distribution ...
- SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung canceron March 4, 2021 at 9:07 pm
Alternative splicing is a critical process to generate protein diversity. However, whether and how alternative splicing regulates autophagy remains largely elusive. Here we systematically identify the ...
- Amgen adds gastric cancer drug candidate in $1.9 billion Five Prime Therapeutics dealon March 4, 2021 at 10:59 am
Drugmaker Amgen Inc will pay about $1.9 billion in cash for Five Prime Therapeutics, adding a late-stage gastric cancer drug candidate to its line of cancer drugs, the companies said on Thursday.
- PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins Sairiyo Therapeutics Scientific and Clinical Advisory Boardon March 4, 2021 at 10:57 am
PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") wholly-owned subsidiary, Sariyo Therapeutics Inc. ("Sairiyo"), a biotechnology company focused on the research and ...
- Amgen to Buy Five Prime for $1.9B to Boost Cancer-Drug Pipelineon March 4, 2021 at 8:54 am
Amgen affirmed its full-year outlook after agreeing to pay $1.9 billion cash for Five Prime in an effort to boost its cancer-drug pipeline.
- Global Cancer Therapeutics Market Outlook, Industry Analysis and Prospect 2016 -2027on March 4, 2021 at 3:40 am
The "Global Cancer Therapeutics Market- - Industry Analysis, Share, Trend, Market Size and Forecast" was estimated to ...
- Dutch cancer biotech LAVA Therapeutics files for a $100 million US IPOon March 2, 2021 at 2:32 pm
L AVA Therapeutics, a Dutch Phase 1/2a biotech developing novel bispecific antibodies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. The company ...
- Anticancer Biosciences is developing a new antimitotic cancer therapeutics using natural productson March 1, 2021 at 11:10 pm
Anticancer Biosciences is applying its synthetic lethality expertise for better cancer therapies. The identification of novel antimitotic agents that do not lead to ...
via Bing News